Expert Ratings For NewAmsterdam Pharma

4 analysts have shared their evaluations of NewAmsterdam Pharma NAMS during the recent three months, expressing a mix of bullish and bearish perspectives.

The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.

Analysts have set 12-month price targets for NewAmsterdam Pharma, revealing an average target of $33.75, a high estimate of $37.00, and a low estimate of $31.00. Marking an increase of 2.27%, the current average surpasses the previous average price target of $33.00.

Decoding Analyst Ratings: A Detailed Look

The standing of NewAmsterdam Pharma among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to NewAmsterdam Pharma. This insight gives a snapshot of analysts' perspectives on the current state of the company.
• Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of NewAmsterdam Pharma compared to the broader market.
• Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.

Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of NewAmsterdam Pharma's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.

Stay up to date on NewAmsterdam Pharma analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

All You Need to Know About NewAmsterdam Pharma

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

Understanding the Numbers: NewAmsterdam Pharma's Finances

Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.

Revenue Growth: NewAmsterdam Pharma's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 32.73%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: NewAmsterdam Pharma's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -1711.58%, the company may face hurdles in effective cost management.

Return on Equity (ROE): NewAmsterdam Pharma's ROE stands out, surpassing industry averages. With an impressive ROE of -9.76%, the company demonstrates effective use of equity capital and strong financial performance.

Return on Assets (ROA): NewAmsterdam Pharma's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -8.34%, the company may encounter challenges in delivering satisfactory returns from its assets.

Debt Management: NewAmsterdam Pharma's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.0.

Analyst Ratings: What Are They?

Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.

Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.

Breaking: Wall Street's Next Big Mover

Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.

This article was generated by Benzinga's automated content engine and reviewed by an editor.